You can buy or sell Genmab and other stocks, options, ETFs, and crypto commission-free!
Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer. Read More Its antibody product, Arzerra used in the treatment of chronic lymphocytic leukemia indications; and DARZALEX. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel in 1999 and is headquartered in Copenhagen, Denmark. GMXAY is listed on the Pink Current market tier. OTC market data is provided by OTC Markets Group, Inc (otcmarkets.com).
Copenhagen, Capital Region
52 Week High
52 Week Low
Yahoo FinanceMay 13
Why Earnings Season Could Be Great for Genmab
Investors are always looking for stocks that are poised to beat at earnings season and Genmab A/S GNMSF may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report. That is because Genmab is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator ...
Seeking AlphaMay 12
Genmab A/S CEO Jan van de Winkel on Q1 2019 Results - Earnings Call Transcript
Genmab A/S (OTCPK:GNMSF) Q1 2019 Earnings Conference Call May 8, 2019 12:00 PM ET Company Participants Jan van de Winkel - Co-Founder, CEO and President David Eatwell - EVP and CFO Conference Call Participants Wimal Kapadia - Sanford C. Bernstein & Co. Thomas Bowers - Danske Bank Sachin Jain - Bank of America Merrill Lynch James Quigley - JPMorgan Chase & Co. Michael Novod - Nordea Peter Welford - Jefferies Jack Scannell - UBS Graig Suvannavejh - Goldman Sachs Operator Good afternoon, ladies a...
Markets InsiderMay 8